Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano
Hiroki
H
Yamamoto
Go
G
Hosoi
Masataka
M
Takahashi
Tsuyoshi
T
Hangaishi
Akira
A
Kurokawa
Mineo
M
D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D000079982:Gemtuzumab; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D000922:Immunotoxins / Q000627:therapeutic use*; D007948:Leukemia, Monocytic, Acute / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000097:blood* / Q000235:genetics; D018365:Neoplasm, Residual / Q000188:drug therapy; D015514:Oncogene Proteins, Fusion / Q000097:blood* / Q000235:genetics; D012074:Remission Induction
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000922:Immunotoxins; C474558:MLL-AF9 fusion protein, human; D015514:Oncogene Proteins, Fusion; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D000079982:Gemtuzumab; D015255:Idarubicin; D003630:Daunorubicin